IL244029B - Deoxycytodine kinase inhibitors - Google Patents

Deoxycytodine kinase inhibitors

Info

Publication number
IL244029B
IL244029B IL24402916A IL24402916A IL244029B IL 244029 B IL244029 B IL 244029B IL 24402916 A IL24402916 A IL 24402916A IL 24402916 A IL24402916 A IL 24402916A IL 244029 B IL244029 B IL 244029B
Authority
IL
Israel
Prior art keywords
kinase inhibitors
deoxycytidine kinase
deoxycytidine
inhibitors
kinase
Prior art date
Application number
IL24402916A
Other languages
English (en)
Hebrew (he)
Other versions
IL244029A0 (en
Original Assignee
Univ California
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Univ Illinois filed Critical Univ California
Publication of IL244029A0 publication Critical patent/IL244029A0/en
Publication of IL244029B publication Critical patent/IL244029B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
IL24402916A 2013-08-13 2016-02-08 Deoxycytodine kinase inhibitors IL244029B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361865468P 2013-08-13 2013-08-13
PCT/US2014/050931 WO2015023776A2 (fr) 2013-08-13 2014-08-13 Inhibiteurs de désoxycytidine kinase

Publications (2)

Publication Number Publication Date
IL244029A0 IL244029A0 (en) 2016-04-21
IL244029B true IL244029B (en) 2019-10-31

Family

ID=52468801

Family Applications (1)

Application Number Title Priority Date Filing Date
IL24402916A IL244029B (en) 2013-08-13 2016-02-08 Deoxycytodine kinase inhibitors

Country Status (11)

Country Link
US (2) US9598404B2 (fr)
EP (1) EP3033340B1 (fr)
JP (1) JP6542216B2 (fr)
KR (1) KR102330566B1 (fr)
CN (1) CN105658648B (fr)
AU (1) AU2014306673B2 (fr)
BR (1) BR112016003019A2 (fr)
CA (1) CA2920738A1 (fr)
EA (1) EA036177B1 (fr)
IL (1) IL244029B (fr)
WO (1) WO2015023776A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA036177B1 (ru) * 2013-08-13 2020-10-09 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Ингибиторы дезоксицитидинкиназы
CA3010723A1 (fr) 2016-01-08 2017-07-13 The Regents Of The University Of California Composes de liaison a la desoxycytidine kinase
CN106421790B (zh) * 2016-11-25 2018-12-25 复旦大学附属金山医院 Cmpk的抑制剂在制备治疗卵巢癌的药物中的应用
CN109134354B (zh) * 2018-09-19 2022-03-25 天津科技大学 2-吡啶甲基硫醚的合成方法及相关药物的合成工艺
EP4237421A1 (fr) 2020-11-02 2023-09-06 Trethera Corporation Formes cristallines d'un inhibiteur de la désoxycytidine kinase et leurs utilisations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080014657A1 (en) 2006-07-12 2008-01-17 Beckton Dickinson And Company Use of Albumin, Bovine, P-Aminophenyl N-Acetyl B-D Glucosaminide as a Control Line for an Immunoassay Device
US8093246B2 (en) * 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
WO2010151735A2 (fr) * 2009-06-25 2010-12-29 Amgen Inc. Composés hétérocycliques et leurs utilisations
KR20130116358A (ko) * 2011-02-09 2013-10-23 에프. 호프만-라 로슈 아게 Pi3 키나아제 억제제로서 헤테로사이클릭 화합물
US9688673B2 (en) * 2011-03-08 2017-06-27 The Regents Of The University Of California Deoxycytidine kinase binding compounds
EP2518071A1 (fr) * 2011-04-29 2012-10-31 Almirall, S.A. Dérivés d'imidazopyridine en tant qu'inhibiteurs PI3K
EP2518070A1 (fr) * 2011-04-29 2012-10-31 Almirall, S.A. Dérivés de pyrrolotriazinon en tant qu'inhibiteurs PI3K
WO2013071232A1 (fr) * 2011-11-11 2013-05-16 Beta Cat Pharmaceuticals, Llc Compositions et procédés pour l'inhibition de la liaison de la tbl-1 à des molécules associées à une maladie
EA036177B1 (ru) * 2013-08-13 2020-10-09 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Ингибиторы дезоксицитидинкиназы

Also Published As

Publication number Publication date
EP3033340A2 (fr) 2016-06-22
BR112016003019A2 (pt) 2017-09-12
KR20160058785A (ko) 2016-05-25
AU2014306673B2 (en) 2018-12-06
IL244029A0 (en) 2016-04-21
CN105658648B (zh) 2020-03-17
JP2016530266A (ja) 2016-09-29
US9598404B2 (en) 2017-03-21
KR102330566B1 (ko) 2021-11-25
EP3033340A4 (fr) 2017-01-25
EA036177B1 (ru) 2020-10-09
CA2920738A1 (fr) 2015-02-19
AU2014306673A1 (en) 2016-03-03
US20160237076A1 (en) 2016-08-18
EP3033340B1 (fr) 2019-12-04
JP6542216B2 (ja) 2019-07-10
WO2015023776A2 (fr) 2015-02-19
CN105658648A (zh) 2016-06-08
EA201690376A1 (ru) 2016-07-29
WO2015023776A3 (fr) 2015-11-12
US20170204090A1 (en) 2017-07-20
US9981961B2 (en) 2018-05-29

Similar Documents

Publication Publication Date Title
HK1220459A1 (zh) 激酶抑制劑
HK1226073A1 (zh) 凋亡信號調節激酶的抑制劑
HK1217198A1 (zh) 蛋白激酶抑制劑
HK1215795A1 (zh) 鵝膏毒素衍生物
SG11201600062RA (en) Pyrimidine derivatives as kinase inhibitors
HK1214813A1 (zh) 激酶抑制劑
HK1211578A1 (en) Amidoimidazopyridazines as mknk-1 kinase inhibitors mknk-1
PL2953944T3 (pl) Pochodne pirydazynonowe-amidowe
HK1217294A1 (zh) '- '- '-氟- '-甲基取代的核苷衍生物
HK1219104A1 (zh) 激酶抑制劑
HK1218119A1 (zh) 蛋白激酶抑制劑
HK1216531A1 (zh) 新的抑制劑
EP3007689A4 (fr) Inhibiteurs de kinase non sélectifs
PT3027598T (pt) Derivados de oxoquinazolinil-butanamida
IL245737A0 (en) Glucosylceramide synthase inhibitors
PL3087076T3 (pl) Pochodne imidazopirazynonowe
IL244029B (en) Deoxycytodine kinase inhibitors
EP2999472A4 (fr) Inhibiteurs d'aurora kinase
GB201307155D0 (en) Kinase inhibitors
GB201300087D0 (en) Dram

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed